Skip to main content

Loading market data...

RGEN

Repligen Corporation

NASDAQ • United states

$180.01

+$1.13

(+0.63%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

Repligen Corporation (RGEN)

Unavailable

Quotes may be delayed

$8.81B

Market Cap

903,856

Volume

257.2

P/E Ratio

Unavailable

Div Yield

Repligen Corporation Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 41 SEYON STREET, WALTHAM, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

7 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Repligen Corporation.

6 Oct 2026

Repligen Corporation reported An acquisition or sale of significant assets

Repligen Corporation filed an 8-K covering an acquisition or sale of significant assets, Regulation FD disclosure, supporting financial statements or exhibits.

30 Sep 2026

Repligen Corporation business combination filing

Repligen Corporation filed Form 425 (communications about a business combination).

16 Sep 2026

Repligen Corporation reported A director or senior management change or compensation event

Repligen Corporation filed an 8-K covering a director or senior management change or compensation event.

9 Sep 2026

Repligen Corporation business combination filing

Repligen Corporation filed Form 425 (communications about a business combination).

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$606.78M

Total assets (USD)$2.95B

Total liabilities (USD)$838.15M

Shareholders' equity (USD)$2.11B

Long-term debt (USD)$551.05M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2018	$44.83M	$5.98M	$3.45M	$0.08	10-Q · 8 May 2018
Q4 2017	$41.61M	$3.26M	$12.18M	$0.27	10-K · 22 Feb 2018
Q3 2017	$36.58M	−$406,000	$4.67M	$0.11	10-Q · 9 Nov 2017
Q2 2017	$32.46M	$5.47M	$8.44M	$0.24	10-Q · 3 Aug 2017
Q1 2017	$30.59M	$5.68M	$3.07M	$0.09	10-Q · 4 May 2017
Q4 2016	$25.60M	$2.91M	$5.03M	$0.15	10-K · 23 Feb 2017

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $202.50

12.5% upside potential

📈

Strong Buy

Unavailable

👍

Buy

8

⏸️

Hold

1

📉

Sell

0

9 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 08:47 UTC Targets range 180.00–225.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

6

Oct 2026

Douglass Brian Robb

CHIEF PRODUCT OFFICER

Grant or award

Unavailable per share

700 shares

5

Oct 2026

Loeillot Olivier

Director, Chief Executive Officer

Open-market sale

$187.29 per share

5,535 shares

5

Oct 2026

Loeillot Olivier

Director, Chief Executive Officer

Option exercise

$154.96 per share

4,202 shares

2

Oct 2026

Loeillot Olivier

Director, Chief Executive Officer

Tax withholding

$181.70 per share

1,248 shares

25

Sep 2026

Garland Jason K

CFO

Tax withholding

$189.68 per share

421 shares

24

Sep 2026

Loeillot Olivier

Director, Chief Executive Officer

Option exercise

$155.11 per share

12,946 shares

24

Sep 2026

Loeillot Olivier

Director, Chief Executive Officer

Open-market sale

$190.00 per share

12,946 shares

21

Sep 2026

Loeillot Olivier

Director, Chief Executive Officer

Option exercise

$141.79 per share

5,426 shares

21

Sep 2026

Loeillot Olivier

Director, Chief Executive Officer

Open-market sale

$180.00 per share

5,426 shares

4

Sep 2026

Loeillot Olivier

Director, Chief Executive Officer

Open-market sale

$165.90 per share

3,035 shares

Top Shareholders

Blackrock, Inc.

6,304,292 shares

-8.274% change

6/30/2026

Vanguard Group Inc

5,439,146 shares

-0.602% change

12/31/2025

Fmr Llc

3,469,896 shares

11.976% change

6/30/2026

United Capital Financial Advisors, Llc

2,790,650 shares

0.601% change

6/30/2026

Vanguard Capital Management Llc

2,694,392 shares

0.799% change

6/30/2026

Vanguard Portfolio Management Llc

2,444,512 shares

0.604% change

6/30/2026

T. Rowe Price Investment Management, Inc.

2,385,133 shares

3.481% change

6/30/2026

State Street Corp

2,039,315 shares

1.727% change

6/30/2026

Maverick Capital Ltd

1,984,554 shares

30.665% change

6/30/2026

Massachusetts Financial Services Co /Ma/

1,772,652 shares

12.896% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 08:47 UTC· 1 hour ago

Research coverage and investment tools

Repligen Corporation (RGEN) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$180.01 on 21 Oct 2026. That is 81% of the way from its 52-week low of US$100.99 to its 52-week high of US$198.87. Its market capitalisation was US$8.81 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2018	$44.83M	$5.98M	$3.45M	$0.08	56.1%	13.3%	$8,000	10-Q · 8 May 2018 (opens in a new tab)
Q4 2017	$41.61M	$3.26M	$12.18M	$0.27	54.0%	7.8%	$13.45M	10-K · 22 Feb 2018 (opens in a new tab)
Q3 2017	$36.58M	−$406,000	$4.67M	$0.11	45.4%	-1.1%	−$2.74M	10-Q · 9 Nov 2017 (opens in a new tab)
Q2 2017	$32.46M	$5.47M	$8.44M	$0.24	57.1%	16.9%	—	10-Q · 3 Aug 2017 (opens in a new tab)
Q1 2017	$30.59M	$5.68M	$3.07M	$0.09	54.3%	18.6%	—	10-Q · 4 May 2017 (opens in a new tab)
Q4 2016	$25.60M	$2.91M	$5.03M	$0.15	—	11.3%	—	10-K · 23 Feb 2017 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/28/2026	$0.54	$0.45	+20.0%
Mar 2026	5/5/2026	$0.48	$0.38	+26.3%
Dec 2025	2/24/2026	$0.49	$0.44	+11.4%
Sep 2025	10/28/2025	$0.46	$0.42	+9.5%

Cash and equivalents: $606.78M
Total assets: $2.95B
Total liabilities: $838.15M
Shareholders' equity: $2.11B
Long-term debt: $551.05M

SCHEDULE 13G/A · 7 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Repligen Corporation.
8-K · 6 Oct 2026 · Merger or acquisition Completed

Repligen Corporation reported An acquisition or sale of significant assets (opens in a new tab)

Repligen Corporation filed an 8-K covering an acquisition or sale of significant assets, Regulation FD disclosure, supporting financial statements or exhibits.
425 · 30 Sep 2026 · Merger or acquisition Announced

Repligen Corporation business combination filing (opens in a new tab)

Repligen Corporation filed Form 425 (communications about a business combination).
8-K · 16 Sep 2026 · Management change

Repligen Corporation reported A director or senior management change or compensation event (opens in a new tab)

Repligen Corporation filed an 8-K covering a director or senior management change or compensation event.
425 · 9 Sep 2026 · Merger or acquisition Announced

Repligen Corporation business combination filing (opens in a new tab)

Repligen Corporation filed Form 425 (communications about a business combination).

Insider	Date	Transaction	Shares	Average price	Filing
Douglass Brian Robb CHIEF PRODUCT OFFICER	6 Oct 2026	Grant or award (A)	+700	—	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	5 Oct 2026	Open-market sale (S)	−5,535	$187.29	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	5 Oct 2026	Option exercise (M)	+4,202	$154.96	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	2 Oct 2026	Tax withholding (F)	−1,248	$181.70	Form 4 (opens in a new tab)
Garland Jason K CFO	25 Sep 2026	Tax withholding (F)	−421	$189.68	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	24 Sep 2026	Option exercise (M)	+12,946	$155.11	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	24 Sep 2026	Open-market sale (S)	−12,946	$190.00	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	21 Sep 2026	Option exercise (M)	+5,426	$141.79	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	21 Sep 2026	Open-market sale (S)	−5,426	$180.00	Form 4 (opens in a new tab)
Loeillot Olivier Director, Chief Executive Officer	4 Sep 2026	Open-market sale (S)	−3,035	$165.90	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	6,304,292	-8.274%
Vanguard Group Inc	12/31/2025	5,439,146	-0.602%
Fmr Llc	6/30/2026	3,469,896	11.976%
United Capital Financial Advisors, Llc	6/30/2026	2,790,650	0.601%
Vanguard Capital Management Llc	6/30/2026	2,694,392	0.799%
Vanguard Portfolio Management Llc	6/30/2026	2,444,512	0.604%
T. Rowe Price Investment Management, Inc.	6/30/2026	2,385,133	3.481%
State Street Corp	6/30/2026	2,039,315	1.727%
Maverick Capital Ltd	6/30/2026	1,984,554	30.665%
Massachusetts Financial Services Co /Ma/	6/30/2026	1,772,652	12.896%

Previous close: 178.88 USD
Day range: 172.01 – 183.48 USD
52-week range: 100.99 – 198.87 USD
Volume: 903,856
Market cap: $8.81B
Average volume: 1,099,876
P/E ratio: 257.2
EPS (TTM, diluted): 0.70 USD
Shares outstanding: 48.92M
Beta (5Y monthly): 1.11

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 14 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:08 UTC· 2 hours ago

P/E is the price ÷ trailing 12-month diluted EPS from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for RGEN yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.